Onconano Medicine近日宣布，其合作伙伴吉利德科学拥有扩展现有合作协议的选项权。根据协议条款，吉利德科学可通过为Onconano Medicine的on-Board技术平台指定额外靶点来触发协议扩展，此举将使Onconano Medicine获得最高达3亿美元的潜在收益。
该选项机制为双方合作提供了灵活性，既体现了吉利德科学对on-Board技术平台的持续认可，也展现出Onconano Medicine在肿瘤纳米医学领域的创新价值。若吉利德科学行使该选项权，Onconano Medicine将获得包括里程碑付款在内的综合收益，进一步强化其研发资金储备。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.